Time-limited venetoclax–obinutuzumab was the predominant first-line regimen, while continuous BTK inhibitor therapy remained nearly as common, and chemoimmunotherapy was rarely selected. Enrichment ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Most metaphors of aging suggest that after a certain point, we are over the hill and face an inevitable decline. If you eat your veggies and get in your steps, the common-sense view goes, you may be ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Regulatory clearance enables an all-oral, fixed-duration acalabrutinib–venetoclax regimen for previously untreated CLL/SLL, expanding beyond continuous BTK inhibition paradigms. AMPLIFY met its ...

With a reverse mortgage, homeowners aged 62 or older can tap a valuable asset for cash without making monthly payments. Instead, payment is due when you sell the house, stop living in the house ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

At first glance, some of the language looks familiar. A letter sent to state officials in Rhode Island by the Justice Department in June included a reminder that federal civil rights law "prohibits an ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...